Watchlist Price Alert

Lyra Therapeutics Inc. (LYRA)

NASDAQ: LYRA · Real-Time Price · USD

20.36

15.43 (312.98%)

At close: Jun 02, 2025, 3:59 PM

312.98% (1D)

Bid	22
Market Cap	26.98M
Revenue (ttm)	1.19M
Net Income (ttm)	-79.53M
EPS (ttm)	-60.5
PE Ratio (ttm)	-0.34
Forward PE	-7.52
Analyst	Hold

Ask	22.99
Volume	26,429,007
Avg. Volume (20D)	69,104
Open	28.71
Previous Close	4.93
Day's Range	5.01 - 37.50
52-Week Range	3.81 - 37.50
Beta	0.05

About LYRA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol LYRA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for LYRA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 day ago New

+310.75%

Lyra Therapeutics shares are trading higher after ... Unlock content with Pro Subscription

6 months ago

-28.07%

Lyra Therapeutics shares are trading lower after the company reported worse-than-expected Q3 sales results.

News

22 hours ago · finbold.com

This penny stock just spiked 550% in a day; Time to buy?

Lyra Therapeutics (NASDAQ: LYRA) ‘s shares surged 550% in pre-market trading on Monday following a breakthrough in its drug trials.

23 hours ago · benzinga.com

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

Lyra Therapeutics, Inc. LYRA released results on Monday from the ENLIGHTEN 2 Phase 3 trial of LYR-210 in adult patients with Chronic Rhinosinusitis (CRS).

4 weeks ago · zacks.com

Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates

Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.35 per share a year ago.